Equine infectious anemia virus (EIAV) is a lentivirus in the genes into cultured human cells. In addition, stable helper retrovirus family of viruses. Replication-defective EIAV veccell lines were created by modifying human 293 cells to tors have been constructed that encode bacterial puromyexpress EIAV proteins. Unlike retroviral vectors based on cin-N-acetyl transferase and E. coli ␤-galactosidase. These murine leukemia virus, EIAV lentiviral vectors transduce vectors could be prepared with titers greater than 10 5 infecnondividing (aphidicolin-arrested) cells. These properties tious units/ml and were able to act as vehicles to carry make EIAV vectors promising gene transfer vehicles.
Introduction
Retroviruses have received considerable attention as gene transfer vectors because they efficiently integrate their genome into host chromosomal DNA and, thus, offer the potential for long-term expression. However, several technical problems have limited the use of retroviruses as vectors for direct in vivo delivery. These limitations include low gene transfer titers and an inability of vectors derived from murine leukemia virus (MuLV) to transduce nondividing cells. 1 Recent experimental approaches have specifically addressed these limitations. One approach has taken advantage of earlier observations 2, 3 to show that it is possible to efficiently pseudotype retroviral vectors with the envelope glycoprotein (G) from vesicular stomatitis virus (VSV). 4 The advantages of VSV-G pseudotyping are two-fold. First, the host range of VSV-G is extremely broad. Second, VSV-G pseudotyped retroviral vectors are sufficiently stable to be concentrated by pelleting using centrifugation techniques.
A second approach for improving retroviral vectors for in vivo delivery has been the use of lentiviral vectors based upon human immunodeficiency virus (HIV). [5] [6] [7] [8] Lentivirus-based vectors have the ability to infect and integrate viral DNA into nondividing cells 6 and thus overcome the major limitation of MuLV-based retroviral vectors. Recent studies have shown the utility of VSV-G pseudotyped HIV vectors to transduce nondividing neurons and other cell types by direct injection in vivo. 6, 7, [9] [10] [11] [12] In addition, four of the accessory proteins (Vif, Vpr, Vpu and Nef), thought to have roles in HIV pathogenesis, can be dispensed with for efficient gene transfer to some, but not all, tissues. 10, 12 A considerable amount of effort is underway to ensure the safety of HIV vectors since safety Correspondence: JC Olsen Received 2 February 1998; accepted 30 June 1998 concerns could limit the use of this vector system in gene therapy clinical trials.
An alternative lentivirus-based approach would be to develop vectors from lentiviruses nonpathogenic for humans. Lentiviruses have been isolated from many vertebrate species including non-human primates, ie the simian immunodeficiency viruses, as well as non-primates, eg feline immunodeficiency virus (FIV), bovine immunodeficiency virus, Visna-Maedi virus and equine infectious anemia virus (EIAV). As a class, lentiviruses share many properties including a similar genome organization, a similar replication cycle, and the ability to infect mature macrophages. 13 From a vector development viewpoint, many of these viruses have a severely restricted host range, and it is not known if lentiviruses whose natural hosts are non-primates can be manipulated to act as vehicles for gene delivery to human cells. A recent report describes the construction of vectors based upon FIV.
14 In this study, we explored the feasibility of using lentiviral vectors based upon EIAV. The normal host range of EIAV includes horses, donkeys and mules. There are no reported cases of human infection by EIAV. However, several features of EIAV biology make this virus an attractive virus to develop as a gene transfer system. 15 Like other lentiviruses, EIAV is capable of infecting mature macrophages, and thus, has the potential to infect quiescent cells. Compared with other lentiviruses, EIAV has a relatively simple genome organization. EIAV has only three regulatory/accessory genes (tat, rev and S2), besides the usual retroviral gag, pol and env genes. Also, a number of infectious molecular DNA clones of EIAV have been described and virus preparations derived from many of these clones are capable of replicating to high titer in cultured permissive cells.
15,16

Results
Construction of plasmids for generating EIAV-based vectors
The starting material for the construction of the EIAV vectors was a plasmid (pER2.1, Figure 1 ), encoding an infectious EIAV DNA clone. 17 Initially, a three plasmid expression system was designed to generate viral vectors by using a transient transfection strategy in human 293 cells. To provide for efficient expression, each plasmid used the major immediate-early promoter from human cytomegalovirus (CMV) to drive transcription. The threeplasmid components of this system include ( Figure 1 ):
EIAV gag/pol expression vector: The pEV53 plasmid was designed to express EIAV proteins required for assembly and release of viral particles from cells and includes genes encoding proteins from the gag and pol genes as well as genes encoding the regulatory proteins Rev and Tat. The organization of the EIAV genome is unusual for lentiviruses in that the first exon of tat precedes the gag gene. The open reading frame S2, encoding a protein whose function is unknown, 18 was also maintained. Two deletions of sequences in the viral env gene were made, including a 736 nt internal deletion in the SU coding region and a deletion of 168 nt of the C-terminus of the TM coding region. Sequence elements at the 3Ј region of the genome required for viral reverse transcription and integration, including the polypurine tract and the entire 3Ј LTR, were deleted. These mutations exclude the possi- bility of this plasmid generating replication-competent EIAV. Sequences at the 5Ј end of the genome including the putative, but as yet undefined, RNA encapsidation signal were left intact.
EIAV gene transfer vector:
The pECX plasmid was designed to serve as the vector for gene transfer and contains all cis-acting sequence elements required to support reverse transcription and integration of the vector genome and a multiple cloning site for insertion of cDNAs encoding genes of interest. Sequences containing the poorly defined EIAV Rev responsive element were not included. 19 Since the EIAV transcriptional enhancer/ promoter functions poorly in human cells, 20 the CMV enhancer/promoter was substituted for the U3 domain of the 5Ј LTR. In these CMV/R/U5 constructs, the transcription start site was placed to be identical with the EIAV start site at the boundary of the R domain, analogous to a previous study with MuLV. 21 For testing purposes, several vectors ( Figure 2 ) were constructed and contained cDNAs encoding the ␤-galactosidase reporter gene (lacZ) or the puromycin-N-acetyl transferase dominant selectable marker gene (puro).
Viral envelope gene expression vector:
The third component of the plasmid expression system is a plasmid that expresses a viral envelope gene (since env in pEV53 was mutated). For these experiments, the vesicular stomatitis virus (VSV) envelope glycoprotein (G) was expressed from a plasmid previously constructed by us for generation of VSV-G pseudotyped MuLV vectors. 22, 23 Production and testing of EIAV vectors EIAV vectors were produced by CaPO 4 -mediated transient transfection of human 293 cells, as described previously. 23 The three-plasmid cotransfection included the pEV53 gag-pol expression plasmid, the pCI-VSV-G expression plasmid and either a puro or lacZ expression vector plasmid (Figure 2 ). At 48 h after transfection, culture medium was harvested from the cells and tested for EIAV vector production using a human CF airway epithelial cell line (CFT1 cells) to measure lacZ expression or murine NIH 3T3 cells for measurement of puromycinresistant colony formation. It was found that EIAV vec-
Figure 2 EIAV vector constructs and titers. All vectors contain the CMV immediate-early gene enhancer/promoter fused precisely to the R/U5 region of the 5Ј LTR sequence. The titer is given in infectious units/ml using host cells described in the text and is the average value of three separate vector preparations.
tors were capable of transferring genes to both cell types. The titer of the lacZ-containing vector containing an internal CMV promoter (pEC-lacZ) was about 6 × 10 4 infectious units/ml using human CFT1 cells as a target. A second lacZ vector (pEM-lacZ) containing the MoloneyMuLV LTR enhancer/promoter region (NheI-SmaI fragment) had a titer of 7 × 10 4 infectious units/ml. In contrast a vector without an internal promoter (pEX-lacZ) had a titer of only 1 × 10 2 infectious units/ml on CFT1 cells. Similar lacZ titers for pEC-lacZ (5 × 10 4 infectious units/ml and pEX-lacZ (1 × 10 2 infectious units/ml) were obtained on equine dermal fibroblasts (NBL-6 cells), a cell line permissive for EIAV replication. The titer of the puromycin containing vector (pEC-puro) was 2 × 10 5 c.f.u./ml using NIH 3T3 cells. Similar puromycin titers were obtained on human 293 cells.
Several control experiments were performed to test whether the expression of the puro and lacZ genes was indeed mediated by viral components. In the first experiment, it was found that gene transfer by the pEC-puro or pEC-lacZ vectors required both the pEV53 viral protein expression vector and the env gene expression vector. This result is consistent with gene transfer and expression mediated by virus and not free DNA. In a second control experiment using the lacZ vector, cells were stained with X-gal immediately after a 2 h infection and no blue cells were found. This result is inconsistent with pseudotransduction, 24 involving the passive transfer of ␤-galactosidase to cells, and suggests that de novo synthesis of ␤-galactosidase is required.
Construction of an EIAV helper cell line (PEV-17 cells)
The pEV53 vector contains sequences from the pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA) including a neo gene for selection in eukaryotic cells. To determine if stable 293 cells expressing EIAV proteins could be generated, we transfected cells with linearized pEV53. Thirty G418-resistant colonies were picked and tested for the ability to complement virus production following a twoplasmid transfection consisting of pEC-lacZ and pCI-VSV-G. Of the 30 clones tested, 22 were found to support vector production under these conditions. One of these clones (PEV-17) was considerably better than others in helper activity and consistently yielded vector titers equal to or better than those obtained in transfection experiments with pEV53. The PEV-17 cell line has had stable helper activity for over 6 months (data not shown). This result suggests the feasibility of generating stable packaging cell lines for EIAV vector production. Figure 2 demonstrated that an internal enhancer/promoter was important for transduction efficiency. The relatively low titer of the EX-lacZ vector might be explained, in part, by the expected rearrangement of LTR sequences that occurs during reverse transcription to generate an intact EIAV LTR at the 5Ј end, which is known to be a poor promoter of transcription in human cells. 20 Also, accumulation of full-length RNA might be expected to be low due to the absence of the Rev responsive element in the vector constructs. 19 Northern analysis was performed on cells harvested 7 days following infection by the EC-lacZ vector to determine the complexity of RNA species produced (Figure 3 ). In these experiments, vector-specific RNA was analyzed from EC-lacZ-transduced normal equine dermal fibroblasts (NBL-6 cells), normal human fibroblasts (IMR-90 cells) and immortalized human airway epithelial cells (CFT1 cells). With all three cell lines, a single major RNA species was detected whose size was consistent with that of the predicted internal CMV promoter-driven 4.0-kb transcript. In contrast, in PEV-17 cells transfected with pEC-lacZ plasmid DNA, a larger 5.4-kb band was detected as well as the 4.0-kb RNA band. The 5.4-kb RNA is consistent with the size expected for a full length RNA species.
Northern analysis of transduced cells Results obtained in the experiment shown in
Figure 3 Expression of the EIAV EC-lacZ vector. At the top of the figure is a diagram of the EC-lacZ vector
Test for replication-competent lentivirus (RCL)
To determine if there was gross RCL generated during virus production, we performed marker rescue assays using 293 cells. Cells were infected with EC-lacZ virus generated from either PEV-17 cells or from a three-plas-mid cotransfection of 293 cells. In these experiments, about 60% of the cells stained positive for lacZ expression when analyzed either 2 days or 10 days after infection. At either 2 days or 10 days after infection, supernatant from the EC-lacZ-infected cells was harvested and used to transduce naive 293 cells. It was found that no lacZcontaining virus could be transferred. We also tested for the possibility that helper function could be transferred to infected cells and that the EC-lacZ provirus was nonrescuable into virus, perhaps due to low steady-state levels of full-length RNA. We therefore carried out a series of transfection experiments to detect helper activity (EIAV proteins or VSV-G) in infected 293 cells using various combinations of the three-plasmid transfection components (helper plasmids and pEC-lacZ). In no case could we find helper activity in cells infected 2 days or 10 days previously. Interestingly, the EC-lacZ genome in EC-lacZ-infected 293 cells was found to be non-rescuable following cotransfection of pEV53 and pCI-VSV-G. The simplest explanation for this is that there is little accumulation of full-length EC-lacZ RNA in infected 293 cells.
Similarly, no RCL could be detected after infection of pEC-lacZ preparations on EIAV-permissive equine dermal fibroblasts (NBL-6 cells), as detected by either assaying for reverse transcriptase (RT) activity 25 in tissue culture supernatant or by using a nested RT-PCR assay for detection of EIAV gag sequences. 26 In these experiments, tissue culture supernatant (10 ml) was harvested 1 month after infection, filtered through an 0.2 m syringe filter, and subjected to ultracentrifugation to pellet virus (100 000 g, 2 h, 4°C). All of the pelleted material from 10-ml tissue culture supernatant was used in either an RT assay or in an RT-PCR assay. The sensitivity of the RT-PCR assay was such that it was capable of detecting approximately 60 copies of EIAV gag-containing RNA per 10 ml of tissue culture supernatant tested (data not shown). These results suggest that significant levels of RCL are not generated using the present vector system. Gene transfer to nondividing cells EIAV, like other lentiviruses and unlike MuLV-derived vectors, is capable of infecting mature macrophages and thus has the potential to infect nondividing cells. Previous studies using HIV-derived vectors have shown that lentiviruses can efficiently transfer and express genes in nondividing cells. 6 As an initial test to see if this property holds for vectors derived from EIAV, human CFT1 airway epithelial cells were arrested in the cell cycle by using aphidicolin treatment and then infected with the EC-lacZ vector. As a control, cells were infected in parallel with VSV-G-pseudotyped HIT-LZ, a lacZ-containing retroviral vector derived from MuLV. 23 At the time of infection, parallel cultures were pulsed with BrdU for 2 h and analyzed for BrdU incorporation into DNA to test the efficacy of the aphidicolin block. It was found that in aphidicolin-treated cultures, the incorporation of BrdU into DNA was inhibited by greater than 90% at the time of infection (Figure 4a) . At 48 h after infection, parallel cultures were stained for lacZ expression with X-Gal. Microscopic fields of stained cells are shown in Figure  4b . As expected, the MuLV-derived vector efficiently infected cells not treated with aphidicolin, however, when cells were arrested in the cell cycle by aphidicolin treatment, gene transfer efficiency dropped markedly (Figure 4b and c) . These results are in agreement with
Figure 4 EIAV-mediated gene transfer to dividing and nondividing human cells. Human CFT1 cells were growth-arrested by aphidicolin treatment and infected with MuLV-based or EIAV-based lacZ-containing vectors. (a) BrdU incorporation into DNA at the time of infection (n = 3). (b) Microscopic images of dividing cells and aphidicolin-treated nondividing cells stained with X-gal for lacZ expression 48 h after infection. Note that there are significantly fewer cells in the aphidicolin-treated samples. (c) Transduction efficiency. Cultures (n = 3) were fixed and stained with X-gal in suspension. The percentage of blue staining cells was determined by using a hemacytometer to count cells.
what others have observed with MuLV-derived vectors. 27, 28 Contrasting results were obtained with the EClacZ vector. Aphidicolin treatment had no significant effect on the percentage of cells infected by the EC-lacZ vector (Figure 4b and c) . These results suggest that EIAV vectors can transfer genes to nondividing human cells.
Discussion
The overall goal of this study was to test the feasibility of generating gene transfer vectors derived from EIAV, a non-primate lentivirus. Our strategy was to construct separate plasmids encoding EIAV proteins, a viral envelope, and an EIAV vector, respectively. Furthermore, in an attempt to broaden the host range of the vector to human cells, we used non-EIAV enhancer/promoter elements to drive expression and a non-EIAV envelope glycoprotein (Figure 1 ). Analogous strategies have been used previously to generate replication-defective MuLVbased retroviral vectors, 4, 21, 29, 30 and HIV-based or FIVbased lentiviral vectors. 6, 14 In our initial experiments, a three-plasmid cotransfection of 293 cells was used to generate virus. Later experiments used PEV-17 helper cells which were stably transfected with the pEV53 EIAV protein expression vector. Both methods were capable of generating EIAV vectors with titers in the 10 4 -10 5 infectious units/ml range. Although this level of gene transfer efficiency was sufficient to transduce up to about 60-70% of human CFT1 cells in a culture dish, this level of transduction is about 100-fold lower than that obtained using analogous procedures in our laboratory to generate MuLV-based vectors. 23 None the less, the EIAV vector reagents described in this report should be useful for future EIAV vector development and for addressing certain issues pertinent to lentiviral vector-mediated gene transfer. For example, we have used the reagents described here as starting materials in a study designed to define the cis-acting sequence elements important for encapsidation of EIAV RNA into virions (M Patel and JCO, unpublished results).
In our experience to date, we have been unable to detect transfer of helper function to target cells based upon marker rescue experiments, reverse transcriptase assays, or PCR tests. Thus, it is unlikely that the gene transfer efficiencies we observe are due to virus spread by recombinant replication-competent lentivirus. It should be noted that the EIAV protein expression cassette (pEV53) used in these experiments contained several cisacting sequences at the 5Ј end important for viral replication including the primer binding site for initiation of DNA synthesis and the putative EIAV encapsidation site. However, pEV53 lacks sequences at the 3Ј-end important for reverse transcription and integration and thus cannot be propagated as a retroviral genome. We are currently testing versions of EIAV protein expression cassettes that lack 5Ј cis-acting replication sequences to prevent the transfer of EIAV genes to target cells.
An interesting aspect of lentiviral gene transfer is the ability to transfer genes to nondividing cells. For HIV-1, redundant mechanisms allow for the efficient nuclear transport of the HIV-1 preintegration complex. This process can be mediated by any one of three karyophilic HIV-1 proteins, including the viral matrix, Vpr, or integrase proteins. [31] [32] [33] [34] For EIAV, the identity of viral proteins involved in the nuclear transport process and possible redundancies in this process are unknown. The observation that EIAV-based vectors can mediate gene transfer and expression to nondividing human cells may suggest that nuclear targeting mechanisms of equine and human lentiviruses are functionally conserved.
The studies presented here suggest the feasibility of developing gene transfer vectors based upon EIAV. With further modifications, it should be possible to increase gene transfer efficiencies while minimizing the potential for generating replication-competent viruses by recombination events. Thus, the development of an EIAV-based vector system may be useful for the safe and efficient in vivo delivery of genes for therapeutic purposes.
Materials and methods
Cell culture
Human 293 cells (clone 293.101), 23 a transformed fetal kidney cell line, were cultured in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Gaithersburg, MD, USA) with high glucose (4.5 g/l) and 10% fetal bovine serum. CFT1 cells, an immortalized cell line derived from the tracheal epithelium of an individual with cystic fibrosis, were cultured in Ham's F12+7X growth medium, as described previously. 35 NIH-3T3 mouse cells (ATCC CRL 1658; Rockville, MD, USA) were maintained in DMEM with high glucose and 10% calf serum. IMR-90 cells are normal human fetal lung fibroblasts (ATCC CCL 186) and were cultured in Eagle's minimum essential medium (MEM) with Earle's salts, 10% fetal bovine serum and with 0.1 mm non-essential amino acid (NEAA) solution. NBL-6 cells are normal equine dermal fibroblasts (ATCC CCL-57) and were cultured in Eagle's MEM with Earle's salts, 10% fetal bovine serum and 0.1 mm NEAA. PEV-17 cells were derived from 293 cells (clone 101) by stable transfection of the pEV53 plasmid (Figure 1) . PEV-17 cells were maintained in DMEM with high glucose, 10% fetal bovine serum, and 800 g/ml (active) G418. All cells were cultured at 37°C and 5% CO 2 .
Construction of plasmids
The starting material for the construction of the EIAV vectors was a plasmid, pER2.1, 17 which was obtained from Dr Frederick Fuller (North Carolina State University, Raleigh, NC, USA). pER2.1 encodes an infectious DNA clone derived from the Malmquist tissue-culture adapted strain of Wyoming EIAV. The positions of EIAV nucleotides referred to below correspond to GenBank accession M87581.
To construct pEV53, an oligonucleotide containing an AscI restriction endonuclease site was first ligated with NheI-HindIII digested pcDNA3.1(+) (Invitrogen Corporation, San Diego, CA, USA) to yield pcDNA3.1-Asc I. A 1.2-kbp HindIII-SpeI fragment (nt 6477-7680 from pER2.1) was cloned into the HindIII-XbaI site of pcDNA3.1-Asc I to form pEV3. A 5.6-kbp MluI-HindIII fragment (nt 121-5741 from pER2.1) was ligated with AscI-HindIII-digested pEV3 to yield pEV53. pEV53 contains a deletion of nt 5742-6476 from the env gene and is deleted of all EIAV sequences downstream of nt 7680 including the 3Ј end of the env gene, the polypurine tract used to initiate second strand DNA synthesis, and the entire 3Ј LTR.
To construct the gene transfer vectors the 3Ј LTR and adjacent polypurine tract from pER2.1 was amplified by PCR using the primer pairs AAGGAAAAAAGCGGCC GCACCATCGATAGAAAAACAAGGGGGGAAC and TCGGAGATCTCCTTAATTAATGTAGGATCTCGAAC AGACAAAC. The 0.35-kbp PCR product was digested with NotI and BglII and cloned into NotI-BamHI digested pCI (Promega Corporation, Madison, WI, USA) to yield pCI-3ЈLTR. To fuse the R and U5 domains of the 5Ј LTR to the CMV promoter, PCR was used to first amplify the 5Ј end of the EIAV genome in pER2.1 (including some gag sequences) by using primer pairs AAGCAGAG CTCGTTTAGTGAACCGGGCACTCAGATTCTGCGGTC and CGGCTAGCTAGCGGAGATTGATCACGTGGATC CATCTGCTTTTGTCCTGCC. The 0.85-kbp PCR product was then digested with SacI and NheI and ligated with SacI-NheI digested pCI-3ЈLTR to yield pEX. pEX was used to insert restriction enzyme fragments containing the CMV or MuLV promoter elements and the lacZ or puromycin genes to yield the vectors shown in Figures 1  and 2 .
The construction of pCI-VSV-G and the plasmids (pCI-GPZ and pHIT-LZ) used to generate MuLV-based vectors have been described previously. 23 
Preparation of viral vectors
All viral vectors were produced by transient transfection. The VSV-G pseudotyped MuLV HIT-LZ vector was pro-duced as described previously. 23 For production of EIAV vectors, 293.101 cells or PEV-17 cells were plated at 1.0-1.2 × 10 7 cells per 10-cm tissue culture plate. Twenty-four hours after plating, the medium was replaced with 6 ml fresh medium and the cells were transfected with 7.5 g each of the helper plasmids (pCI-VSV-G and pEV53, 293.101 cells; pCI-VSV-G, PEV-17 cells) and 7.5 g of the EIAV vector plasmid using calcium phosphate coprecipitation. 36 Cells were transfected overnight and fed with medium containing 10 mm sodium butyrate. 21, 37 Twentyfour hours after addition of sodium butyrate, the viruscontaining medium was harvested, filtered through a 0.2 m filter, and stored at −80°C. For some experiments (eg Figure 3) , VSV-G pseudotyped EIAV vectors were concentrated about 50-fold before use by ultracentrifugation, as described previously. 23, 38 The yield of concentrated virus, based upon recovery of total infectivity, ranged from 40 to 60%.
Virus-mediated gene transfer
Cells were plated at 10 5 cells per well in 12-well plates. The day after plating, cells were infected for 2 h at 37°C with various amounts of vector in 1 ml final volume in the presence of 8 g/ml polybrene. In some cases the volumes in the wells were adjusted to 2 ml and then centrifuged in a microtiter plate carrier at 200 g for 30 min at room temperature. 39 This spin-inoculation protocol increased transduction efficiency about five-fold.
For determination of puromycin resistance titer, cells were passaged at 24 h after infection into 10-cm plates containing 3 g/ml puromycin in growth medium. The medium was changed every 2-3 days. At 7-10 days, at which time mock-infected control plates had completely cleared, the medium was removed and the colonies were stained with 0.4% crystal violet in 50% ethanol and counted. Virus titer in colony-forming units/ml was calculated by multiplying the total number of colonies by the dilution factor.
For determination of X-gal staining titer, cells were removed from plates with 0.5 ml trypsin at 48 h after infection. An equal volume of growth medium was added and the cells were pelleted, suspended in 0.1 ml medium, and fixed in suspension with 1 ml 0.5% glutaraldehyde in phosphate-buffered saline solution (PBS) for 10 min at room temperature. Cells were pelleted and washed twice with 1 ml PBS containing 1 mm MgCl 2 . Cells were then stained in X-gal solution 40 for 2 h at 37°C and the number of stained and unstained cells was determined by counting using a hemacytometer. Virus titer in infectious units per milliliter was determined by multiplying the fraction of cells staining positive with Xgal by the number of cells infected and by the dilution factor.
Aphidicolin treatment and BrdU labeling
On the day before infection, CFT1 cells were plated in growth medium containing 2 g/ml aphidicolin (Calbiochem-Novabiochem, La Jolla, CA, USA). Cells were infected with vectors in the presence of aphidicolin and maintained in aphidicolin until analysis.
For BrdU labeling, CFT1 cells were labeled with 40 m 5-bromo-deoxyuridine (BrdU) for 2 h at 37°C. Cells were analyzed for BrdU incorporation using a commercial kit (BrdU Labeling and Detection Kit II; Boehringer Mannheim, Indianapolis, IN, USA).
Northern analysis
Total RNA was extracted from cultured cells by the single-step method 41 using TRI Reagent (Molecular Research Center, Cincinnati, OH, USA). RNA from transfected cells was further purified by oligo(dT) cellulose chromatography (MessageMaker mRNA Isolation System; Life Technologies). Total RNA (20 g per lane) or purified polyadenylated RNA (2 g per lane) was subjected to electrophoresis in 1.2% agarose-formaldehyde gels (4-mm thick). 42 The estimated sizes of RNA transcripts were calculated from the mobility of RNA markers run in an adjacent lane. Blotting to neutral nylon membranes (Max-S Nytran; Schleicher & Scheull, Keene, NH, USA) and hybridization was performed as described. 43 The 32 P-DNA probe was generated by randomly priming a purified lacZ-specific 3.5-kbp DNA fragment using a commercial kit (Rediprime; Amersham Life Science, Arlington Heights, IL, USA).
